Selected research
Industry Research
Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Research Report 2026
Market perspective
The global Tumor Necrosis Factor Receptor Superfamily Member 9 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Tumor Necrosis Factor Receptor Superfamily Member 9 market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Tumor Necrosis Factor Receptor Superfamily Member 9 market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Tumor Necrosis Factor Receptor Superfamily Member 9 market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Tumor Necrosis Factor Receptor Superfamily Member 9 include Eli Lilly and Co, Pfizer Inc, Pieris Pharmaceuticals Inc, MacroGenics Inc, Juno Therapeutics Inc, BioInvent International AB, Apogenix GmbH, Alligator Bioscience AB and Agenus Inc. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Tumor Necrosis Factor Receptor Superfamily Member 9 market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Tumor Necrosis Factor Receptor Superfamily Member 9.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Company
Eli Lilly and Co
Pfizer Inc
Pieris Pharmaceuticals Inc
MacroGenics Inc
Juno Therapeutics Inc
BioInvent International AB
Apogenix GmbH
Alligator Bioscience AB
Agenus Inc
Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Type
Ultra-41BBL
PRS-342
ISAS-01
EU-101
Others
Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Application
Gastric Cancer
Lymphoma
Cervical Cancer
Bladder Cancer
Others
Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Receptor Superfamily Member 9 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Receptor Superfamily Member 9 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Receptor Superfamily Member 9.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Tumor Necrosis Factor Receptor Superfamily Member 9 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ultra-41BBL
- PRS-342
- ISAS-01
- EU-101
- Others
Applications
- Gastric Cancer
- Lymphoma
- Cervical Cancer
- Bladder Cancer
- Others
Companies covered
- Eli Lilly and Co
- Pfizer Inc
- Pieris Pharmaceuticals Inc
- MacroGenics Inc
- Juno Therapeutics Inc
- BioInvent International AB
- Apogenix GmbH
- Alligator Bioscience AB
- Agenus Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Tumor Necrosis Factor Receptor Superfamily Member 9 by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Ultra-41BBL
- 2.2.3 PRS-342
- 2.2.4 ISAS-01
- 2.2.5 EU-101
- 2.2.6 Others
- 2.3 Tumor Necrosis Factor Receptor Superfamily Member 9 by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Gastric Cancer
- 2.3.3 Lymphoma
- 2.3.4 Cervical Cancer
- 2.3.5 Bladder Cancer
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Tumor Necrosis Factor Receptor Superfamily Member 9 Breakdown Data by Type
- 3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Historic Market Size by Type (2021-2026)
- 3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Type (2027-2032)
4 Tumor Necrosis Factor Receptor Superfamily Member 9 Breakdown Data by Application
- 4.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Historic Market Size by Application (2021-2026)
- 4.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Perspective (2021-2032)
- 5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Growth Trends by Region
- 5.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Historic Market Size by Region (2021-2026)
- 5.2.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Region (2027-2032)
- 5.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Dynamics
- 5.3.1 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Trends
- 5.3.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Drivers
- 5.3.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Challenges
- 5.3.4 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Tumor Necrosis Factor Receptor Superfamily Member 9 Players by Revenue
- 6.1.1 Global Top Tumor Necrosis Factor Receptor Superfamily Member 9 Players by Revenue (2021-2026)
- 6.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Players (2021-2026)
- 6.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Tumor Necrosis Factor Receptor Superfamily Member 9 Head Office and Area Served
- 6.4 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Players, Product Type & Application
- 6.5 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Manufacturers Established Date
- 6.6 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
- 7.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
- 7.4 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
- 8.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
- 8.4 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
- 9.2 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
- 10.2 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
- 10.4 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
- 11.2 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eli Lilly and Co
- 12.1.1 Eli Lilly and Co Company Information
- 12.1.2 Eli Lilly and Co Business Overview
- 12.1.3 Eli Lilly and Co Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.1.4 Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.1.5 Eli Lilly and Co Recent Developments
- 12.2 Pfizer Inc
- 12.2.1 Pfizer Inc Company Information
- 12.2.2 Pfizer Inc Business Overview
- 12.2.3 Pfizer Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.2.4 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.2.5 Pfizer Inc Recent Developments
- 12.3 Pieris Pharmaceuticals Inc
- 12.3.1 Pieris Pharmaceuticals Inc Company Information
- 12.3.2 Pieris Pharmaceuticals Inc Business Overview
- 12.3.3 Pieris Pharmaceuticals Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.3.4 Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.3.5 Pieris Pharmaceuticals Inc Recent Developments
- 12.4 MacroGenics Inc
- 12.4.1 MacroGenics Inc Company Information
- 12.4.2 MacroGenics Inc Business Overview
- 12.4.3 MacroGenics Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.4.4 MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.4.5 MacroGenics Inc Recent Developments
- 12.5 Juno Therapeutics Inc
- 12.5.1 Juno Therapeutics Inc Company Information
- 12.5.2 Juno Therapeutics Inc Business Overview
- 12.5.3 Juno Therapeutics Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.5.4 Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.5.5 Juno Therapeutics Inc Recent Developments
- 12.6 BioInvent International AB
- 12.6.1 BioInvent International AB Company Information
- 12.6.2 BioInvent International AB Business Overview
- 12.6.3 BioInvent International AB Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.6.4 BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.6.5 BioInvent International AB Recent Developments
- 12.7 Apogenix GmbH
- 12.7.1 Apogenix GmbH Company Information
- 12.7.2 Apogenix GmbH Business Overview
- 12.7.3 Apogenix GmbH Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.7.4 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.7.5 Apogenix GmbH Recent Developments
- 12.8 Alligator Bioscience AB
- 12.8.1 Alligator Bioscience AB Company Information
- 12.8.2 Alligator Bioscience AB Business Overview
- 12.8.3 Alligator Bioscience AB Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.8.4 Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.8.5 Alligator Bioscience AB Recent Developments
- 12.9 Agenus Inc
- 12.9.1 Agenus Inc Company Information
- 12.9.2 Agenus Inc Business Overview
- 12.9.3 Agenus Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.9.4 Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.9.5 Agenus Inc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst